{"id":473806,"date":"2025-06-11T00:00:00","date_gmt":"2025-06-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0023-2025-biopharma-gastroesophageal-cancer-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-03-31T10:26:02","modified_gmt":"2026-03-31T10:26:02","slug":"cutron0023-2025-biopharma-gastroesophageal-cancer-current-treatment-current-treatment-physician-insights","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0023-2025-biopharma-gastroesophageal-cancer-current-treatment-current-treatment-physician-insights\/","title":{"rendered":"Gastroesophageal Cancer &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Gastroesophageal Cancer (US)"},"content":{"rendered":"<p>The gastroesophageal cancer therapy market is gaining a lot of traction. In the HER2-positive segment, trastuzumab-based regimens, with or without Keytruda, continue to dominate. Meanwhile, the HER2-negative setting is on the brink of a significant transformation. Immune checkpoint inhibitors such as Opdivo and Keytruda have achieved unparalleled penetration into all populations and lines of therapy. The FDA\u2019s anticipated restriction of PD-1 inhibitors to PD-L1-expressing tumors, coupled with the approval of the first-in-class claudin 18.2 inhibitor Vyloy, will further reshape market dynamics in this space.<\/p>\n<p><b>QUESTIONS ANSWERED<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment rates for gastroesophageal cancer in the various settings and lines of therapy?<\/li>\n<\/ul>\n<ul class=\"BulletListStyle1 SCXW88372892 BCX0 round-bullets\">\n<li>What is Vyloy\u2019s impact on the HER2-negative gastroesophageal cancer market?<\/li>\n<\/ul>\n<ul class=\"BulletListStyle1 SCXW88372892 BCX0 round-bullets\">\n<li>What are the leading therapies in the treatment of HER2-positive gastroesophageal cancer?<\/li>\n<\/ul>\n<ul class=\"BulletListStyle1 SCXW88372892 BCX0 round-bullets\">\n<li>What do surveyed oncologists consider the main drivers of and key obstacles to the uptake of select therapies?<\/li>\n<\/ul>\n<p><b>PRODUCT DESCRIPTION<\/b><\/p>\n<div>\n<p style=\"\">Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW2798998 BCX0 round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW2798998 BCX0 round-bullets\">\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW2798998 BCX0 round-bullets\">\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW2798998 BCX0 round-bullets\">\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n<\/div>\n<p><b>Markets covered: <\/b>United States<\/p>\n<p><b>Primary research: <\/b>Survey of 100 medical oncologists in the United States fielded in April 2025.<\/p>\n<p><b>Key drugs: <\/b>Cyramza, Enhertu, Herceptin, Keytruda, Lonsurf, Opdivo, Tevimbra, Vyloy, Yervoy<\/p>\n","protected":false},"template":"","class_list":["post-473806","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/473806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/473806\/revisions"}],"predecessor-version":[{"id":575778,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/473806\/revisions\/575778"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=473806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}